Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance

Fei Su, Songyeon Ahn, Achinto Saha, John DiGiovanni, Mikhail G. Kolonin

Research output: Contribution to journalArticle

8 Citations (Scopus)

Abstract

Fat tissue, overgrowing in obesity, promotes the progression of various carcinomas. Clinical and animal model studies indicate that adipose stromal cells (ASC), the progenitors of adipocytes, are recruited by tumors and promote tumor growth as tumor stromal cells. Here, we investigated the role of ASC in cancer chemoresistance and invasiveness, the attributes of tumor aggressiveness. By using human cell co-culture models, we demonstrate that ASC induce epithelial-mesenchymal transition (EMT) in prostate cancer cells. Our results for the first time demonstrate that ASC interaction renders cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. To confirm these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prostate tumors. We show that obesity promotes EMT in cancer cells and tumor invasion into the surrounding fat tissue. A hunter-killer peptide D-CAN, previously developed for targeted ASC ablation, suppressed the obesity-associated EMT and cancer progression. Importantly, cisplatin combined with D-CAN was more effective than cisplatin alone in suppressing growth of mouse prostate cancer allografts and xenografts even in non-obese mice. Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combination cancer therapy.

Original languageEnglish (US)
Pages (from-to)1979-1988
Number of pages10
JournalOncogene
Volume38
Issue number11
DOIs
StatePublished - Mar 14 2019

Fingerprint

Epithelial-Mesenchymal Transition
Stromal Cells
Prostatic Neoplasms
Neoplasms
Cisplatin
Obesity
docetaxel
Fats
Obese Mice
Growth
Coculture Techniques
Adipocytes
Heterografts
Cell Communication
Allografts
Prostate
Animal Models

ASJC Scopus subject areas

  • Molecular Biology
  • Genetics
  • Cancer Research

Cite this

Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance. / Su, Fei; Ahn, Songyeon; Saha, Achinto; DiGiovanni, John; Kolonin, Mikhail G.

In: Oncogene, Vol. 38, No. 11, 14.03.2019, p. 1979-1988.

Research output: Contribution to journalArticle

Su, Fei ; Ahn, Songyeon ; Saha, Achinto ; DiGiovanni, John ; Kolonin, Mikhail G. / Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance. In: Oncogene. 2019 ; Vol. 38, No. 11. pp. 1979-1988.
@article{a924119e63614d2b9ff92792ac419681,
title = "Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance",
abstract = "Fat tissue, overgrowing in obesity, promotes the progression of various carcinomas. Clinical and animal model studies indicate that adipose stromal cells (ASC), the progenitors of adipocytes, are recruited by tumors and promote tumor growth as tumor stromal cells. Here, we investigated the role of ASC in cancer chemoresistance and invasiveness, the attributes of tumor aggressiveness. By using human cell co-culture models, we demonstrate that ASC induce epithelial-mesenchymal transition (EMT) in prostate cancer cells. Our results for the first time demonstrate that ASC interaction renders cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. To confirm these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prostate tumors. We show that obesity promotes EMT in cancer cells and tumor invasion into the surrounding fat tissue. A hunter-killer peptide D-CAN, previously developed for targeted ASC ablation, suppressed the obesity-associated EMT and cancer progression. Importantly, cisplatin combined with D-CAN was more effective than cisplatin alone in suppressing growth of mouse prostate cancer allografts and xenografts even in non-obese mice. Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combination cancer therapy.",
author = "Fei Su and Songyeon Ahn and Achinto Saha and John DiGiovanni and Kolonin, {Mikhail G.}",
year = "2019",
month = "3",
day = "14",
doi = "10.1038/s41388-018-0558-8",
language = "English (US)",
volume = "38",
pages = "1979--1988",
journal = "Oncogene",
issn = "0950-9232",
publisher = "Nature Publishing Group",
number = "11",

}

TY - JOUR

T1 - Adipose stromal cell targeting suppresses prostate cancer epithelial-mesenchymal transition and chemoresistance

AU - Su, Fei

AU - Ahn, Songyeon

AU - Saha, Achinto

AU - DiGiovanni, John

AU - Kolonin, Mikhail G.

PY - 2019/3/14

Y1 - 2019/3/14

N2 - Fat tissue, overgrowing in obesity, promotes the progression of various carcinomas. Clinical and animal model studies indicate that adipose stromal cells (ASC), the progenitors of adipocytes, are recruited by tumors and promote tumor growth as tumor stromal cells. Here, we investigated the role of ASC in cancer chemoresistance and invasiveness, the attributes of tumor aggressiveness. By using human cell co-culture models, we demonstrate that ASC induce epithelial-mesenchymal transition (EMT) in prostate cancer cells. Our results for the first time demonstrate that ASC interaction renders cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. To confirm these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prostate tumors. We show that obesity promotes EMT in cancer cells and tumor invasion into the surrounding fat tissue. A hunter-killer peptide D-CAN, previously developed for targeted ASC ablation, suppressed the obesity-associated EMT and cancer progression. Importantly, cisplatin combined with D-CAN was more effective than cisplatin alone in suppressing growth of mouse prostate cancer allografts and xenografts even in non-obese mice. Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combination cancer therapy.

AB - Fat tissue, overgrowing in obesity, promotes the progression of various carcinomas. Clinical and animal model studies indicate that adipose stromal cells (ASC), the progenitors of adipocytes, are recruited by tumors and promote tumor growth as tumor stromal cells. Here, we investigated the role of ASC in cancer chemoresistance and invasiveness, the attributes of tumor aggressiveness. By using human cell co-culture models, we demonstrate that ASC induce epithelial-mesenchymal transition (EMT) in prostate cancer cells. Our results for the first time demonstrate that ASC interaction renders cancer cells more migratory and resistant to docetaxel, cabazitaxel, and cisplatin chemotherapy. To confirm these findings in vivo, we compared cancer aggressiveness in lean and obese mice grafted with prostate tumors. We show that obesity promotes EMT in cancer cells and tumor invasion into the surrounding fat tissue. A hunter-killer peptide D-CAN, previously developed for targeted ASC ablation, suppressed the obesity-associated EMT and cancer progression. Importantly, cisplatin combined with D-CAN was more effective than cisplatin alone in suppressing growth of mouse prostate cancer allografts and xenografts even in non-obese mice. Our data demonstrate that ASC promote tumor aggressiveness and identify them as a target of combination cancer therapy.

UR - http://www.scopus.com/inward/record.url?scp=85055692752&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85055692752&partnerID=8YFLogxK

U2 - 10.1038/s41388-018-0558-8

DO - 10.1038/s41388-018-0558-8

M3 - Article

C2 - 30361686

AN - SCOPUS:85055692752

VL - 38

SP - 1979

EP - 1988

JO - Oncogene

JF - Oncogene

SN - 0950-9232

IS - 11

ER -